Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53

We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc metallochaperones (ZMCs) that restore zinc binding by shuttling zinc into cells. We defined biophysical and cellular assays necessary for structure–act...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 64; no. 4; pp. 2024 - 2045
Main Authors Gilleran, John A, Yu, Xin, Blayney, Alan J, Bencivenga, Anthony F, Na, Bing, Augeri, David J, Blanden, Adam R, Kimball, S. David, Loh, Stewart N, Roberge, Jacques Y, Carpizo, Darren R
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 25.02.2021
Amer Chemical Soc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc metallochaperones (ZMCs) that restore zinc binding by shuttling zinc into cells. We defined biophysical and cellular assays necessary for structure–activity relationship studies using this mechanism. We investigated an alternative class of zinc scaffolds that differ from TSCs by substitution of the thiocarbamoyl moiety with benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones. Members of this series bound zinc with similar affinity and functioned to reactivate mutant p53 comparable to the TSCs. Acute toxicity and efficacy assays in rodents demonstrated C1 to be significantly less toxic than the TSCs while demonstrating equivalent growth inhibition. We identified C85 as a ZMC with diminished copper binding that functions as a chemotherapy and radiation sensitizer. We conclude that the benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones can function as ZMCs to reactivate mutant p53 in vitro and in vivo.
AbstractList We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc metallochaperones (ZMCs) that restore zinc binding by shuttling zinc into cells. We defined biophysical and cellular assays necessary for structure–activity relationship studies using this mechanism. We investigated an alternative class of zinc scaffolds that differ from TSCs by substitution of the thiocarbamoyl moiety with benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones. Members of this series bound zinc with similar affinity and functioned to reactivate mutant p53 comparable to the TSCs. Acute toxicity and efficacy assays in rodents demonstrated C1 to be significantly less toxic than the TSCs while demonstrating equivalent growth inhibition. We identified C85 as a ZMC with diminished copper binding that functions as a chemotherapy and radiation sensitizer. We conclude that the benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones can function as ZMCs to reactivate mutant p53 in vitro and in vivo.
We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc metallochaperones (ZMCs) that restore zinc binding by shuttling zinc into cells. We defined biophysical and cellular assays necessary for structure–activity relationship studies using this mechanism. We investigated an alternative class of zinc scaffolds that differ from TSCs by substitution of the thiocarbamoyl moiety with benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones. Members of this series bound zinc with similar affinity and functioned to reactivate mutant p53 comparable to the TSCs. Acute toxicity and efficacy assays in rodents demonstrated C1 to be significantly less toxic than the TSCs while demonstrating equivalent growth inhibition. We identified C85 as a ZMC with diminished copper binding that functions as a chemotherapy and radiation sensitizer. We conclude that the benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones can function as ZMCs to reactivate mutant p53 in vitro and in vivo .
We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc metallochaperones (ZMCs) that restore zinc binding by shuttling zinc into cells. We defined biophysical and cellular assays necessary for structure-activity relationship studies using this mechanism. We investigated an alternative class of zinc scaffolds that differ from TSCs by substitution of the thiocarbamoyl moiety with benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones. Members of this series bound zinc with similar affinity and functioned to reactivate mutant p53 comparable to the TSCs. Acute toxicity and efficacy assays in rodents demonstrated to be significantly less toxic than the TSCs while demonstrating equivalent growth inhibition. We identified as a ZMC with diminished copper binding that functions as a chemotherapy and radiation sensitizer. We conclude that the benzothiazolyl, benzoxazolyl, and benzimidazolyl hydrazones can function as ZMCs to reactivate mutant p53 and .
Author Yu, Xin
Carpizo, Darren R
Blanden, Adam R
Kimball, S. David
Na, Bing
Bencivenga, Anthony F
Roberge, Jacques Y
Blayney, Alan J
Gilleran, John A
Augeri, David J
Loh, Stewart N
AuthorAffiliation Division of Surgical Oncology, Department of Surgery
Department of Biochemistry and Molecular Biology
Rutgers Molecular Design and Synthesis, Office of Research and Economic Development
Program of Surgical Oncology, Rutgers Cancer Institute of New Jersey
Department of Surgery, Robert Wood Johnson Medical School
University of Rochester Medical Center
Wilmot Cancer Center
AuthorAffiliation_xml – name: Department of Surgery, Robert Wood Johnson Medical School
– name: Division of Surgical Oncology, Department of Surgery
– name: Wilmot Cancer Center
– name: Program of Surgical Oncology, Rutgers Cancer Institute of New Jersey
– name: University of Rochester Medical Center
– name: Rutgers Molecular Design and Synthesis, Office of Research and Economic Development
– name: Department of Biochemistry and Molecular Biology
Author_xml – sequence: 1
  givenname: John A
  surname: Gilleran
  fullname: Gilleran, John A
  organization: Rutgers Molecular Design and Synthesis, Office of Research and Economic Development
– sequence: 2
  givenname: Xin
  surname: Yu
  fullname: Yu, Xin
  organization: Department of Surgery, Robert Wood Johnson Medical School
– sequence: 3
  givenname: Alan J
  surname: Blayney
  fullname: Blayney, Alan J
  organization: Department of Biochemistry and Molecular Biology
– sequence: 4
  givenname: Anthony F
  surname: Bencivenga
  fullname: Bencivenga, Anthony F
  organization: Rutgers Molecular Design and Synthesis, Office of Research and Economic Development
– sequence: 5
  givenname: Bing
  surname: Na
  fullname: Na, Bing
  organization: Department of Surgery, Robert Wood Johnson Medical School
– sequence: 6
  givenname: David J
  surname: Augeri
  fullname: Augeri, David J
  organization: Rutgers Molecular Design and Synthesis, Office of Research and Economic Development
– sequence: 7
  givenname: Adam R
  surname: Blanden
  fullname: Blanden, Adam R
  organization: Department of Biochemistry and Molecular Biology
– sequence: 8
  givenname: S. David
  surname: Kimball
  fullname: Kimball, S. David
  organization: Rutgers Molecular Design and Synthesis, Office of Research and Economic Development
– sequence: 9
  givenname: Stewart N
  surname: Loh
  fullname: Loh, Stewart N
  organization: Department of Biochemistry and Molecular Biology
– sequence: 10
  givenname: Jacques Y
  orcidid: 0000-0002-7810-4139
  surname: Roberge
  fullname: Roberge, Jacques Y
  organization: Rutgers Molecular Design and Synthesis, Office of Research and Economic Development
– sequence: 11
  givenname: Darren R
  surname: Carpizo
  fullname: Carpizo, Darren R
  email: darren.carpizo@urmc.rochester.edu
  organization: Wilmot Cancer Center
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33538587$$D View this record in MEDLINE/PubMed
BookMark eNqNkVtr3DAQhUVJSTaXf1CK3ou3ulha-aXQLklTSCiU5CUvYiyPuw5eabHktJtfH-0lS_tS-qRhdM7R6JtTcuSDR0LecTblTPCP4OL0cYmNW-ByyhzjUrM3ZMKVYEVpWHlEJowJUQgt5Ak5jfGRMSa5kMfkREoljTKzCWm_oH8OadHBc-jXPQXf0G3r975xvW6GXHqM9Gr0LnXBU4j0ofOO3mKCvg9uASsctpIU6A-ErHqChPR2TOATXSl5Tt620Ee82J9n5P7q8m5-Xdx8__pt_vmmgLKsUqFBu6rhLeMCeQtuVjrUznCjGIeq1lJWrlGuNqIuTdvMpODM1KrC1uXvCCnPyKdd7mqsN2zQpwF6uxq6JQxrG6Czf9_4bmF_hidbiZnRSueAchfghhDjgO3By5ndcLeZu33lbvfcs-39n-8eTK-gs-DDTvAL69BG16F3eJDlzWhRSl3JXHGV1eb_1fMuwWYt8zD6lK1sZ93OGcbBZ97_Hv4FBt24LQ
CitedBy_id crossref_primary_10_3390_biom13010159
crossref_primary_10_3389_fmolb_2022_895887
crossref_primary_10_1016_j_cej_2023_146449
crossref_primary_10_1039_D3CC05834D
crossref_primary_10_1016_j_aca_2024_342432
crossref_primary_10_1007_s00775_022_01939_2
crossref_primary_10_1016_j_jphotochem_2022_113827
crossref_primary_10_1016_j_cbpa_2022_102230
crossref_primary_10_3390_biom13111588
crossref_primary_10_3390_inorganics12010026
crossref_primary_10_1128_spectrum_01951_21
crossref_primary_10_1016_j_snb_2021_130426
crossref_primary_10_3390_biomedicines9080852
crossref_primary_10_1039_D3DT00150D
crossref_primary_10_3390_cancers13133344
crossref_primary_10_1016_j_bioorg_2023_106477
crossref_primary_10_1016_j_jinorgbio_2021_111691
crossref_primary_10_1016_j_jinorgbio_2023_112433
crossref_primary_10_2174_0113895575263108231031132404
crossref_primary_10_4274_tpd_galenos_2023_96658
crossref_primary_10_1021_acs_jmedchem_3c01612
Cites_doi 10.1021/acs.jmedchem.6b01050
10.7594/eLife.61487
10.1038/s41523-019-0110-1
10.1007/s00216-018-0889-x
10.1158/1078-0432.CCR-18-0822
10.1007/s10822-011-9478-1
10.1186/s12943-015-0486-y
10.1021/acs.jmedchem.7b00490
10.1002/med.21634
10.1002/ejoc.201700749
10.1016/j.ccr.2012.03.042
10.1101/cshperspect.a000950
10.1038/nature09018
10.1042/BST0361317
10.1158/1535-7163.MCT-18-1080
10.1021/jm060232u
10.1016/j.chembiol.2018.02.010
10.18632/oncotarget.26561
10.1074/jbc.M109.003459
10.3390/toxins12080482
10.1016/j.drudis.2015.07.006
10.1021/jm900552r
10.1124/mol.116.107409
10.1124/mol.114.097550
10.2174/092986709787002817
10.18632/oncotarget.2432
10.1038/sj.onc.1203907
10.1016/S0079-6468(08)70259-5
10.7554/eLife.61487
10.1002/ijc.1427
10.1016/S0021-9258(20)80574-2
10.1016/B978-012369520-8.50017-6
10.1021/jp980230o
10.1126/science.8023157
10.1016/0092-8674(93)90719-7
10.5935/0305-7518.19860115
10.1126/science.7973635
10.1021/jm970255w
ContentType Journal Article
Copyright 2021 American Chemical Society
Copyright_xml – notice: 2021 American Chemical Society
DBID 1KM
1KN
BLEPL
DTL
HGBXW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
DOI 10.1021/acs.jmedchem.0c01360
DatabaseName Index Chemicus
Current Chemical Reactions
Web of Science Core Collection
Science Citation Index Expanded
Web of Science - Science Citation Index Expanded - 2021
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle Web of Science
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList
Web of Science

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 1KN
  name: Current Chemical Reactions
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.CCR
  sourceTypes:
    Enrichment Source
    Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1520-4804
EndPage 2045
ExternalDocumentID 10_1021_acs_jmedchem_0c01360
33538587
000624369300015
a959019834
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
  grantid: F30GM113299
– fundername: Breast Cancer Research Foundation
– fundername: NCI NIH HHS
  grantid: R01 CA200800
– fundername: NCI NIH HHS
  grantid: K08 CA172676
– fundername: NIGMS NIH HHS
  grantid: F30 GM113299
GroupedDBID -
.K2
55A
5GY
5RE
5VS
7~N
AABXI
ABFLS
ABMVS
ABOCM
ABPTK
ABUCX
ACGFS
ACJ
ACS
AEESW
AENEX
AFEFF
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
CS3
DU5
EBS
ED
ED~
F5P
GNL
IH2
IH9
IHE
JG
JG~
K2
L7B
LG6
P2P
ROL
TN5
UI2
VF5
VG9
W1F
WH7
X
XFK
YZZ
ZY4
---
-~X
1KM
1KN
4.4
6P2
AAHBH
ABJNI
ABQRX
ABTAH
ACGFO
ADHLV
AGXLV
AHGAQ
BLEPL
CUPRZ
DTL
GGK
GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED
XSW
YQT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
5PM
ID FETCH-LOGICAL-a449t-6a6c9d1f012e1fac74ce6c818501a9b6339cd5cb82b48fd732108b59efc858233
IEDL.DBID ACS
ISICitedReferencesCount 22
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000624369300015
ISSN 0022-2623
IngestDate Tue Sep 17 21:25:42 EDT 2024
Fri Aug 23 02:50:24 EDT 2024
Sat Sep 28 08:10:37 EDT 2024
Fri Sep 27 16:30:10 EDT 2024
Wed Sep 18 08:24:08 EDT 2024
Sat Feb 27 03:13:00 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords 2-ACETYLPYRIDINE
SITE
2-BENZOXAZOLYL
THIOSEMICARBAZONES
CHELATORS
COPPER
CONFORMATION
BINDING
ANTITUMOR
MOLECULES
Language English
LinkModel DirectLink
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-a449t-6a6c9d1f012e1fac74ce6c818501a9b6339cd5cb82b48fd732108b59efc858233
Notes S.N.L, J.Y.R., and D.R.C. are co-senior authors.
J.G., X.Y., and A.J.B. contributed equally to this work.
Author Contributions
ORCID 0000-0002-7810-4139
0000-0001-6797-8968
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278656
PMID 33538587
PageCount 22
ParticipantIDs crossref_primary_10_1021_acs_jmedchem_0c01360
pubmed_primary_33538587
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9278656
webofscience_primary_000624369300015CitationCount
acs_journals_10_1021_acs_jmedchem_0c01360
webofscience_primary_000624369300015
ProviderPackageCode JG~
55A
AABXI
GNL
VF5
7~N
ACJ
VG9
W1F
ACS
AEESW
AFEFF
.K2
ABMVS
ABUCX
IH9
BAANH
AQSVZ
ED~
UI2
PublicationCentury 2000
PublicationDate 2021-02-25
PublicationDateYYYYMMDD 2021-02-25
PublicationDate_xml – month: 02
  year: 2021
  text: 2021-02-25
  day: 25
PublicationDecade 2020
PublicationPlace WASHINGTON
PublicationPlace_xml – name: WASHINGTON
– name: United States
PublicationTitle Journal of medicinal chemistry
PublicationTitleAbbrev J MED CHEM
PublicationTitleAlternate J. Med. Chem
PublicationYear 2021
Publisher American Chemical Society
Amer Chemical Soc
Publisher_xml – name: American Chemical Society
– name: Amer Chemical Soc
References Shimada, K (WOS:000432448700011) 2018; 25
Lu, J (WOS:000261749200044) 2008; 36
Pelivan, K (WOS:000427465400010) 2018; 410
Easmon, J (WOS:000241192400025) 2006; 49
Blanden, AR (WOS:000599509600001) 2020; 9
Meplan, C (WOS:000165059700003) 2000; 19
CHO, YJ (WOS:A1994NW81600027) 1994; 265
Easmon, J (WOS:000170752600013) 2001; 94
Chandler, P (WOS:000367535200001) 2016; 15
Easmon, J (WOS:000071343300024) 1997; 40
Zaman, S (WOS:000478022400003) 2019; 18
Muehlbacher, M (WOS:000298191600001) 2011; 25
Kerns, EH (WOS:000311101200017) 2008
Yu, X (WOS:000304214100006) 2012; 21
Prasanna, S (WOS:000263294600002) 2009; 16
Yu, X (WOS:000401101800002) 2017; 91
Yu, Xin (MEDLINE:30847017) 2019; 10
Kourounakis, AP (WOS:000485789400001) 2020; 40
MASUOKA, J (WOS:A1993MC80900019) 1993; 268
Cramer, J (WOS:000405764900034) 2017; 60
Lagrange, E (WOS:000564086700001) 2020; 12
LOWE, SW (WOS:A1993LY49300004) 1993; 74
Lokov, M (WOS:000407822200017) 2017; 2017
Agrawal, K C (MEDLINE:400614) 1978; 15
Yu, X (WOS:000348033800005) 2014; 5
Na, B (WOS:000470038500001) 2019; 5
Stacy, AE (WOS:000384035300028) 2016; 59
Ghose, AK (WOS:000073999900019) 1998; 102
Meek, DW (WOS:000279879900002) 2009; 1
HAINAUT, P (WOS:A1993KY09600006) 1993; 53
Blanden, AR (WOS:000365369200015) 2015; 20
Yu, Y (WOS:000269655500001) 2009; 52
Blanden, AR (WOS:000352004600007) 2015; 87
Schaper, K J (MEDLINE:3553814) 1986; 57 Suppl 3
TOTH, B (WOS:A1975AY30900022) 1975; 35
Blindauer, CA (WOS:000268963100063) 2009; 284
LOWE, SW (WOS:A1994PP75300041) 1994; 266
Banci, L (WOS:000278249000048) 2010; 465
Yu, X (WOS:000444768200019) 2018; 24
ref9/cit9
ref6/cit6
ref36/cit36
ref3/cit3
ref27/cit27
ref18/cit18
ref11/cit11
ref25/cit25
ref16/cit16
ref29/cit29
Hainaut P. (ref4/cit4) 1993; 53
ref32/cit32
ref23/cit23
ref39/cit39
ref14/cit14
ref8/cit8
ref5/cit5
ref31/cit31
ref2/cit2
ref34/cit34
ref37/cit37
ref28/cit28
ref40/cit40
ref20/cit20
ref17/cit17
ref10/cit10
Kerns E. H. (ref33/cit33) 2008
ref26/cit26
ref35/cit35
ref19/cit19
ref21/cit21
ref12/cit12
ref15/cit15
ref42/cit42
Toth B. (ref38/cit38) 1975; 35
ref41/cit41
ref22/cit22
ref13/cit13
ref30/cit30
ref1/cit1
ref24/cit24
ref7/cit7
References_xml – volume: 59
  start-page: 8601
  year: 2016
  ident: WOS:000384035300028
  article-title: Structure-Activity Relationships of Di-2-pyridylketone, 2-Benzoylpyridine, and 2-Acetylpyridine Thiosemicarbazones for Overcoming Pgp-Mediated Drug Resistance
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.6b01050
  contributor:
    fullname: Stacy, AE
– start-page: 209
  year: 2008
  ident: WOS:000311101200017
  article-title: hERG Blocking
  publication-title: DRUG-LIKE PROPERTIES: CONCEPTS, STRUCTURE DESIGN AND METHODS
  contributor:
    fullname: Kerns, EH
– volume: 9
  start-page: ARTN e61487
  year: 2020
  ident: WOS:000599509600001
  article-title: Zinc shapes the folding landscape of p53 and establishes a pathway for reactivating structurally diverse cancer mutants
  publication-title: ELIFE
  doi: 10.7594/eLife.61487
  contributor:
    fullname: Blanden, AR
– volume: 5
  start-page: ARTN 14
  year: 2019
  ident: WOS:000470038500001
  article-title: Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
  publication-title: NPJ BREAST CANCER
  doi: 10.1038/s41523-019-0110-1
  contributor:
    fullname: Na, B
– volume: 410
  start-page: 2343
  year: 2018
  ident: WOS:000427465400010
  article-title: Comparison of metabolic pathways of different alpha-N-heterocyclic thiosemicarbazones
  publication-title: ANALYTICAL AND BIOANALYTICAL CHEMISTRY
  doi: 10.1007/s00216-018-0889-x
  contributor:
    fullname: Pelivan, K
– volume: 15
  start-page: 321
  year: 1978
  ident: MEDLINE:400614
  article-title: The chemistry and biological activity of alpha -(N)-heterocyclic carboxaldehyde thiosemicarbazones.
  publication-title: Progress in medicinal chemistry
  contributor:
    fullname: Agrawal, K C
– volume: 266
  start-page: 807
  year: 1994
  ident: WOS:A1994PP75300041
  article-title: P53 STATUS AND THE EFFICACY OF CANCER-THERAPY IN-VIVO
  publication-title: SCIENCE
  contributor:
    fullname: LOWE, SW
– volume: 24
  start-page: 4505
  year: 2018
  ident: WOS:000444768200019
  article-title: Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer Therapeutics
  publication-title: CLINICAL CANCER RESEARCH
  doi: 10.1158/1078-0432.CCR-18-0822
  contributor:
    fullname: Yu, X
– volume: 25
  start-page: 1095
  year: 2011
  ident: WOS:000298191600001
  article-title: Qualitative prediction of blood-brain barrier permeability on a large and refined dataset
  publication-title: JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
  doi: 10.1007/s10822-011-9478-1
  contributor:
    fullname: Muehlbacher, M
– volume: 102
  start-page: 3762
  year: 1998
  ident: WOS:000073999900019
  article-title: Prediction of hydrophobic (lipophilic) properties of small organic molecules using fragmental methods: An analysis of ALOGP and CLOGP methods
  publication-title: JOURNAL OF PHYSICAL CHEMISTRY A
  contributor:
    fullname: Ghose, AK
– volume: 15
  start-page: ARTN 2
  year: 2016
  ident: WOS:000367535200001
  article-title: Subtype-specific accumulation of intracellular zinc pools is associated with the malignant phenotype in breast cancer
  publication-title: MOLECULAR CANCER
  doi: 10.1186/s12943-015-0486-y
  contributor:
    fullname: Chandler, P
– volume: 60
  start-page: 5791
  year: 2017
  ident: WOS:000405764900034
  article-title: Paying the Price of Desolvation in Solvent-Exposed Protein Pockets: Impact of Distal Solubilizing Groups on Affinity and Binding Thermodynamics in a Series of Thermolysin Inhibitors
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.7b00490
  contributor:
    fullname: Cramer, J
– volume: 40
  start-page: 709
  year: 2020
  ident: WOS:000485789400001
  article-title: Morpholine as a privileged structure: A review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules
  publication-title: MEDICINAL RESEARCH REVIEWS
  doi: 10.1002/med.21634
  contributor:
    fullname: Kourounakis, AP
– volume: 74
  start-page: 957
  year: 1993
  ident: WOS:A1993LY49300004
  article-title: P53-DEPENDENT APOPTOSIS MODULATES THE CYTOTOXICITY OF ANTICANCER AGENTS
  publication-title: CELL
  contributor:
    fullname: LOWE, SW
– volume: 2017
  start-page: 4475
  year: 2017
  ident: WOS:000407822200017
  article-title: On the Basicity of Conjugated Nitrogen Heterocycles in Different Media
  publication-title: EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
  doi: 10.1002/ejoc.201700749
  contributor:
    fullname: Lokov, M
– volume: 35
  start-page: 3693
  year: 1975
  ident: WOS:A1975AY30900022
  article-title: SYNTHETIC AND NATURALLY OCCURRING HYDRAZINES AS POSSIBLE CANCER CAUSATIVE AGENTS
  publication-title: CANCER RESEARCH
  contributor:
    fullname: TOTH, B
– volume: 57 Suppl 3
  start-page: 254
  year: 1986
  ident: MEDLINE:3553814
  article-title: Development of inhibitors of mycobacterial ribonucleotide reductase.
  publication-title: Leprosy review
  contributor:
    fullname: Schaper, K J
– volume: 265
  start-page: 346
  year: 1994
  ident: WOS:A1994NW81600027
  article-title: CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS
  publication-title: SCIENCE
  contributor:
    fullname: CHO, YJ
– volume: 21
  start-page: 614
  year: 2012
  ident: WOS:000304214100006
  article-title: Allele-Specific p53 Mutant Reactivation
  publication-title: CANCER CELL
  doi: 10.1016/j.ccr.2012.03.042
  contributor:
    fullname: Yu, X
– volume: 5
  start-page: 8879
  year: 2014
  ident: WOS:000348033800005
  article-title: Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism
  publication-title: ONCOTARGET
  contributor:
    fullname: Yu, X
– volume: 1
  start-page: ARTN a000950
  year: 2009
  ident: WOS:000279879900002
  article-title: Posttranslational Modification of p53: Cooperative Integrators of Function
  publication-title: COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY
  doi: 10.1101/cshperspect.a000950
  contributor:
    fullname: Meek, DW
– volume: 465
  start-page: 645
  year: 2010
  ident: WOS:000278249000048
  article-title: Affinity gradients drive copper to cellular destinations
  publication-title: NATURE
  doi: 10.1038/nature09018
  contributor:
    fullname: Banci, L
– volume: 53
  start-page: 1739
  year: 1993
  ident: WOS:A1993KY09600006
  article-title: A STRUCTURAL ROLE FOR METAL-IONS IN THE WILD-TYPE CONFORMATION OF THE TUMOR SUPPRESSOR PROTEIN-P53
  publication-title: CANCER RESEARCH
  contributor:
    fullname: HAINAUT, P
– volume: 36
  start-page: 1317
  year: 2008
  ident: WOS:000261749200044
  article-title: Albumin as a zinc carrier: properties of its high-affinity zinc-binding site
  publication-title: BIOCHEMICAL SOCIETY TRANSACTIONS
  doi: 10.1042/BST0361317
  contributor:
    fullname: Lu, J
– volume: 18
  start-page: 1355
  year: 2019
  ident: WOS:000478022400003
  article-title: Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding
  publication-title: MOLECULAR CANCER THERAPEUTICS
  doi: 10.1158/1535-7163.MCT-18-1080
  contributor:
    fullname: Zaman, S
– volume: 19
  start-page: 5227
  year: 2000
  ident: WOS:000165059700003
  article-title: Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells
  publication-title: ONCOGENE
  contributor:
    fullname: Meplan, C
– volume: 49
  start-page: 6343
  year: 2006
  ident: WOS:000241192400025
  article-title: Synthesis, structure-activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm060232u
  contributor:
    fullname: Easmon, J
– volume: 25
  start-page: 585
  year: 2018
  ident: WOS:000432448700011
  article-title: Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells
  publication-title: CELL CHEMICAL BIOLOGY
  doi: 10.1016/j.chembiol.2018.02.010
  contributor:
    fullname: Shimada, K
– volume: 16
  start-page: 21
  year: 2009
  ident: WOS:000263294600002
  article-title: Topological Polar Surface Area: A Useful Descriptor in 2D-QSAR
  publication-title: CURRENT MEDICINAL CHEMISTRY
  contributor:
    fullname: Prasanna, S
– volume: 10
  start-page: 918
  year: 2019
  ident: MEDLINE:30847017
  article-title: Flipping the "switch" on mutant p53 by zinc metallochaperones: how a brief pulse of zinc can reactivate mutant p53 to kill cancer.
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.26561
  contributor:
    fullname: Yu, Xin
– volume: 284
  start-page: 23116
  year: 2009
  ident: WOS:000268963100063
  article-title: Structure, Properties, and Engineering of the Major Zinc Binding Site on Human Albumin
  publication-title: JOURNAL OF BIOLOGICAL CHEMISTRY
  doi: 10.1074/jbc.M109.003459
  contributor:
    fullname: Blindauer, CA
– volume: 12
  start-page: ARTN 482
  year: 2020
  ident: WOS:000564086700001
  article-title: Warning on False or True Morels and Button Mushrooms with Potential Toxicity Linked to Hydrazinic Toxins: An Update
  publication-title: TOXINS
  doi: 10.3390/toxins12080482
  contributor:
    fullname: Lagrange, E
– volume: 20
  start-page: 1391
  year: 2015
  ident: WOS:000365369200015
  article-title: Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer
  publication-title: DRUG DISCOVERY TODAY
  doi: 10.1016/j.drudis.2015.07.006
  contributor:
    fullname: Blanden, AR
– volume: 40
  start-page: 4420
  year: 1997
  ident: WOS:000071343300024
  article-title: Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: Synthesis and antiproliferative activity
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  contributor:
    fullname: Easmon, J
– volume: 268
  start-page: 21533
  year: 1993
  ident: WOS:A1993MC80900019
  article-title: INTRINSIC STOICHIOMETRIC EQUILIBRIUM-CONSTANTS FOR THE BINDING OF ZINC(II) AND COPPER(II) TO THE HIGH-AFFINITY SITE OF SERUM-ALBUMIN
  publication-title: JOURNAL OF BIOLOGICAL CHEMISTRY
  contributor:
    fullname: MASUOKA, J
– volume: 52
  start-page: 5271
  year: 2009
  ident: WOS:000269655500001
  article-title: Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm900552r
  contributor:
    fullname: Yu, Y
– volume: 91
  start-page: 567
  year: 2017
  ident: WOS:000401101800002
  article-title: Thiosemicarbazones Functioning as Zinc Metallochaperones to Reactivate Mutant p53
  publication-title: MOLECULAR PHARMACOLOGY
  doi: 10.1124/mol.116.107409
  contributor:
    fullname: Yu, X
– volume: 87
  start-page: 825
  year: 2015
  ident: WOS:000352004600007
  article-title: Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore
  publication-title: MOLECULAR PHARMACOLOGY
  doi: 10.1124/mol.114.097550
  contributor:
    fullname: Blanden, AR
– volume: 94
  start-page: 89
  year: 2001
  ident: WOS:000170752600013
  article-title: 2-benzoxazolyl and 2-benzimidazolyl hydrazones derived from 2-acetylpyridine: A novel class of antitumor agents
  publication-title: INTERNATIONAL JOURNAL OF CANCER
  contributor:
    fullname: Easmon, J
– ident: ref30/cit30
  doi: 10.2174/092986709787002817
– ident: ref14/cit14
  doi: 10.18632/oncotarget.2432
– ident: ref5/cit5
  doi: 10.1038/sj.onc.1203907
– ident: ref11/cit11
  doi: 10.1016/S0079-6468(08)70259-5
– ident: ref26/cit26
  doi: 10.1021/jm060232u
– ident: ref19/cit19
  doi: 10.7554/eLife.61487
– ident: ref27/cit27
  doi: 10.1002/ijc.1427
– ident: ref37/cit37
  doi: 10.1038/nature09018
– ident: ref1/cit1
  doi: 10.1016/j.drudis.2015.07.006
– ident: ref7/cit7
  doi: 10.1124/mol.116.107409
– volume: 35
  start-page: 3693
  year: 1975
  ident: ref38/cit38
  publication-title: Cancer Res.
  contributor:
    fullname: Toth B.
– ident: ref39/cit39
  doi: 10.3390/toxins12080482
– ident: ref12/cit12
  doi: 10.1021/jm900552r
– ident: ref17/cit17
  doi: 10.1016/S0021-9258(20)80574-2
– ident: ref32/cit32
  doi: 10.1002/med.21634
– ident: ref36/cit36
  doi: 10.1158/1535-7163.MCT-18-1080
– ident: ref10/cit10
  doi: 10.1158/1078-0432.CCR-18-0822
– ident: ref31/cit31
  doi: 10.1007/s10822-011-9478-1
– ident: ref20/cit20
  doi: 10.1021/acs.jmedchem.6b01050
– ident: ref2/cit2
  doi: 10.18632/oncotarget.26561
– ident: ref16/cit16
  doi: 10.1074/jbc.M109.003459
– ident: ref24/cit24
  doi: 10.1007/s00216-018-0889-x
– ident: ref40/cit40
– ident: ref8/cit8
  doi: 10.1016/j.ccr.2012.03.042
– ident: ref23/cit23
– start-page: 209
  volume-title: Drug-Like Properties: Concepts, Structure Design And Methods, From Adme To Toxicity Optimization
  year: 2008
  ident: ref33/cit33
  doi: 10.1016/B978-012369520-8.50017-6
  contributor:
    fullname: Kerns E. H.
– ident: ref28/cit28
– ident: ref13/cit13
  doi: 10.1016/j.chembiol.2018.02.010
– ident: ref21/cit21
  doi: 10.1002/ejoc.201700749
– ident: ref6/cit6
  doi: 10.1124/mol.114.097550
– ident: ref29/cit29
  doi: 10.1021/jp980230o
– ident: ref15/cit15
  doi: 10.1101/cshperspect.a000950
– ident: ref9/cit9
  doi: 10.1038/s41523-019-0110-1
– ident: ref3/cit3
  doi: 10.1126/science.8023157
– ident: ref18/cit18
  doi: 10.1042/BST0361317
– ident: ref35/cit35
  doi: 10.1016/0092-8674(93)90719-7
– volume: 53
  start-page: 1739
  year: 1993
  ident: ref4/cit4
  publication-title: Cancer Res.
  contributor:
    fullname: Hainaut P.
– ident: ref41/cit41
  doi: 10.1021/acs.jmedchem.7b00490
– ident: ref25/cit25
  doi: 10.5935/0305-7518.19860115
– ident: ref34/cit34
  doi: 10.1126/science.7973635
– ident: ref42/cit42
  doi: 10.1186/s12943-015-0486-y
– ident: ref22/cit22
  doi: 10.1021/jm970255w
SSID ssj0003123
Score 2.4947886
Snippet We identified a set of thiosemicarbazone (TSC) metal ion chelators that reactivate specific zinc-deficient p53 mutants using a mechanism called zinc...
Source Web of Science
SourceID pubmedcentral
crossref
pubmed
webofscience
acs
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2024
SubjectTerms Animals
Antineoplastic Agents - chemical synthesis
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Benzothiazoles - chemical synthesis
Benzothiazoles - pharmacology
Benzothiazoles - therapeutic use
Benzoxazoles - chemical synthesis
Benzoxazoles - pharmacology
Benzoxazoles - therapeutic use
Cell Line, Tumor
Chelating Agents - chemical synthesis
Chelating Agents - pharmacology
Chelating Agents - therapeutic use
Chemistry, Medicinal
Humans
Hydrazones - chemical synthesis
Hydrazones - pharmacology
Hydrazones - therapeutic use
Life Sciences & Biomedicine
Mice
Mice, Nude
Molecular Structure
Neoplasms - drug therapy
Pharmacology & Pharmacy
Photosensitizing Agents - chemical synthesis
Photosensitizing Agents - pharmacology
Photosensitizing Agents - therapeutic use
Science & Technology
Structure-Activity Relationship
Tumor Suppressor Protein p53 - drug effects
Tumor Suppressor Protein p53 - metabolism
Xenograft Model Antitumor Assays
Zinc - metabolism
Title Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53
URI http://dx.doi.org/10.1021/acs.jmedchem.0c01360
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000624369300015
https://www.ncbi.nlm.nih.gov/pubmed/33538587
https://pubmed.ncbi.nlm.nih.gov/PMC9278656
Volume 64
WOS 000624369300015
WOSCitedRecordID wos000624369300015
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1ZT9tAEB4h-kBfetDLLa32ASFVwmn28PUIEVGElBa1IKG-WHtZCaUGYadq8uvZ8RVCqYA3az225d3Z_b7VzHwLsB05Ci-yQPl9o7QvEit9bPEZdeBmrDFMYqHw-Gs4OhGHp8HpcqN4O4LP6Bepi94ZJitO7O9eX6PGmNuiP2GYRIhUaPCjW3k5ZbxVB2cO19tSuf-8BQFJFyuA1KHQXRmSt1CpQqDhc_jW1vHUiSe_erNS9fTiX1nHB_7cC3jWkFGyV3vPS1iz-SZsDNoz4DZh56hWtp7vkuNloVaxS3bI0VLzev4Ksn2bL9ygT-Xi4nx-TmRuSNX0t2kYzc2Vu3QLKxk6KEV3ILIgP6e5JmNbYvhfTySqlqNJeUG-Wyy5-OOoMBnP8Khjchnw13AyPDgejPzmCAdfCpGUfihDnRiaORi0NJM6EtqGGklCn8pEhZwn2gRaxUyJODMRVhTFKkhspuMgZpy_gfXcffgdEB07emYjFLDPhKZGuithRSiSUFpjlQefXW-mzRQs0iq6zmhaNTZdnDZd7IHfjnl6Wat63GP_tvaHzprzAEOqkQfRiqd0BijbvXonn04q-e6ERbFj0R5s3_Sp7kEkEExwPKISCa0H9CFmg0bRHZUMyveP6IoP8JRhmg5W6QdbsF5ezexHx7NK9amaXNfFiSa1
link.rule.ids 230,315,786,790,891,2782,27109,27957,27958,57093,57143
linkProvider American Chemical Society
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Zb9NAEB5V5aG8cJTLnPtQVUKqQ7yHj0eIiAI0VQUpqnix1rtrJVDcqnYQya9nxrEdUoGgb9Z4fOx61t-32plvAfYipPAyV5nft5nxZeK0TxafBwhu1lnLNRUKj4_C0Yl8f6pOt0C1tTD4EiXeqawX8dfqAsErsn2lnMWp-97rG5Iaw5n6DRXhlJwY0eBT9wMWARetSDhHeG8r5v5yF8IlU27gUgdGf0qUvAJONRANb8Pnrgl1_sm33rzKemZ5Rd3x2m28A7caasper2LpLmy5Yhd2Bu2OcLuwf7zSuV4csMm6bKs8YPvseK2AvbgH-RtXLDEEZnp5frY4Y7qwrDb9bAyjhb3EQ_zNsiECKwUH0yX7MisMG7uKkgHMVJOGOblU5-yjowKMH0iM2XhOGx-zCyXuw8nw7WQw8psNHXwtZVL5oQ5NYoMcQdEFuTaRNC40RBn6gU6yUIjEWGWymGcyzm1E9UVxphKXm1jFXIgHsF3ggx8BMzGSNReRnH0uTWA1HkknQ5mE2lmXefASezNtBmSZ1mvtPEhrY9PFadPFHvjtp08vVhof__B_uAqLzlsIRQuskQfRRsB0DiTivXmmmE1rMe-ERzFyag_2fg-t7kKiE1wK2rCS6K0Hwf-4DRp9d9I1qB5foytewM5oMj5MD98dfXgCNzkl8FD9vnoK29Xl3D1DBlZlz-vx9gvo7y8g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEB6hIgEvBcpRQ4F9qCoh1SF7-XgsgSgcqSJopaov1l5WAsWNageR_Hp2HMdtKhDHmzUeX-tZf5-1M98A7Maewotc6rBrtQlF6lSIlpBRD27WWcsUFgoPD6PBsXh_Ik-utPryN1H6M5X1Ij7O6qnNG4UB-grtXzBvcey-dboG5cb83_pNiT28kRX1PrcfYU4ZXwmFMw_xq6q535wFscmUa9jUAtKvkiWvAVQNRv27cNo-Rp2D8rUzq3THLK4pPP7Xc96DzYaikoNlTN2HG67Ygtu9VWe4LdgbLfWu5_vk6LJ8q9wne2R0qYQ9fwD5a1csfChM1OL8bH5GVGFJbfrRGAZze-E3_eeW9D3AYpAQVZLTSWHI0FWYFGDGCrXM0aU6J58cFmJ89wSZDGfYAJlMJX8Ix_23R71B2DR2CJUQaRVGKjKppbkHR0dzZWJhXGSQOnSpSnXEeWqsNDphWiS5jbHOKNEydblJZMI4fwQbhb_wNhCTeNLmYpS1z4WhVvkt4UQk0kg563QAL_1oZs3ELLN6zZ3RrDY2Q5w1QxxAuHr92XSp9fEH_8fL0Gi9OZe40BoHEK8FTeuAYt7re4rJuBb1TlmceG4dwO7V8GoPRFrBBMfGlUhzA6B_49ZrdN5R36B68g9D8QJujd70s4_vDj88hTsM83iwjF_uwEZ1MXPPPBGr9PN6yv0EXOsxmg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Benzothiazolyl+and+Benzoxazolyl+Hydrazones+Function+as+Zinc+Metallochaperones+to+Reactivate+Mutant+p53&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Gilleran%2C+John+A&rft.au=Yu%2C+Xin&rft.au=Blayney%2C+Alan+J&rft.au=Bencivenga%2C+Anthony+F&rft.date=2021-02-25&rft.eissn=1520-4804&rft.volume=64&rft.issue=4&rft.spage=2024&rft_id=info:doi/10.1021%2Facs.jmedchem.0c01360&rft_id=info%3Apmid%2F33538587&rft.externalDocID=33538587
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon